J Fr Ophtalmol. 2011 Sep;34(7):491-7. doi: 10.1016/j.jfo.2011.04.007. Epub 2011 Jun 21.
Journal francais d'ophtalmologie
[Article in French] P Massin
PMID: 21696846 DOI: 10.1016/j.jfo.2011.04.007
Even if several studies have clearly demonstrated that a good control of glycemia and arterial pressure allow reducing the incidence and the progression of diabetic retinopathy, there is currently no drug treatment to prevent the incidence or progression of diabetic retinopathy. However, significant progress has been made in treating the complications of diabetic retinopathy, including diabetic macular edema. Ranibizumab is effective in improving visual acuity in diabetic macular edema, but at the cost of repeated injections and monthly follow-ups. It has obtained a marketing authorization (MA) in this indication. Injections of intravitreal triamcinolone acetonide are also effective in reducing macular edema and in improving visual acuity but at the cost of significant side effects and without MA for intraocular use. The latter must be proposed after failure and/or injection of anti-VEGF or laser therapy.
Copyright © 2011 Elsevier Masson SAS. All rights reserved.
